Anaptysbio (ANAB) Cash from Investing Activities Growth (1y) (2017 - 2026)
Anaptysbio (ANAB) Cash from Investing Activities Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Anaptysbio | 1.54 Bn | 1.26 Bn | - | 135.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 135.62% |
| Dec 31, 2025 | 350.03% |
| Sep 30, 2025 | 76.19% |
| Jun 30, 2025 | 1,590.70% |
| Mar 31, 2025 | -78.36% |
| Dec 31, 2024 | -159.77% |
| Sep 30, 2024 | 91.35% |
| Jun 30, 2024 | 88.06% |
| Mar 31, 2024 | -19.65% |
| Dec 31, 2023 | 128.77% |
| Sep 30, 2023 | 194.45% |
| Jun 30, 2023 | 71.19% |
| Mar 31, 2023 | 127.29% |
| Dec 31, 2022 | 132.23% |
| Sep 30, 2022 | -399.23% |
| Jun 30, 2022 | -287.02% |
| Mar 31, 2022 | -651.59% |
| Dec 31, 2021 | -1,953.64% |
| Sep 30, 2021 | 129.06% |
| Jun 30, 2021 | -49.65% |